✨ Free AI Report
Biocon Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Biocon Limited
Company Research

Biocon Limited: Business Overview, Financials & Competitive Analysis

Biocon Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Growing biopharmaceutical player with diversified portfolio across generics, biosimilars, and CRDMO services capturing high-growth markets. Current market cap is $6.6B with 1.62B shares. As of 30-Sep-2025, Biocon has a trailing 12-month revenue of $1.9B. Strong biosimilars portfolio and contract manufacturing capabilities position Biocon as a significant player in emerging market.

What is Biocon Limited's industry? Biocon Limited (biocon.com) operates in Biopharmaceuticals & Generic Drugs Manufacturing. AskCyborg classifies Biocon Limited under Biopharmaceuticals & Generic Drugs Manufacturing in its company registry.

Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple scler...

7/ 10Strong

Cyborg Score thesis

Growing biopharmaceutical player with diversified portfolio across generics, biosimilars, and CRDMO services capturing...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals & Generic Drugs Manufacturing
3 named competitors
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Biocon Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Biocon Limited

AskCyborg analysts argue the bull and bear cases for Biocon Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Biocon Limited OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Biocon Limited Overview

Pro stress-test →

Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept.

Strategic Profile

Pro stress-test →

It provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. The company was founded by Kiran Mazumdar-Shaw in 1978. The company operates across generics, biosimilars, and research segments with a global footprint.

Competitive Landscape

Pro stress-test →

Biocon operates in the crowded Indian biopharmaceutical sector competing with other manufacturers and biosimilar developers. Key competitors include Lupin and other Indian pharmaceutical companies. The company differentiates through its biosimilars expertise and contract manufacturing capabilities serving global pharma clients.

Industry Context

Biocon Limited operates in Biopharmaceuticals & Generic Drugs Manufacturing.

Key facts

Founded: 1978 · Headquarters: Bengaluru, India · Employees: 16,561 · Revenue: $1.9B · Market cap: $6.6B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Biocon Limited.

  • Diversified revenue streams across generics, biosimilars, and contract research services reduce dependency on single business segment
  • NSE-listed public company with $6.6B market capitalization and established investor presence in Indian markets
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

LupinIndian pharmaceutical company with global presence→CiplaGeneric and specialty pharmaceutical manufacturer→Dr. Reddy'sPharmaceutical generics and active pharmaceutical ingredients→

Compare Biocon Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Biocon Limited operates in Biopharmaceuticals & Generic Drugs Manufacturing. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals & Generic Drugs Manufacturing research →
NEW · MCP server

Ask your AI assistant about Biocon Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Biocon Limited and its top competitor on Cyborg Score”
“What did Biocon Limited do this quarter?”
“Is Biocon Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Biocon Limited do?+
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple scler...
What is Biocon Limited's Cyborg Score?+
Biocon Limited has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Biocon Limited's main competitors?+
Named competitors include Lupin, Cipla, Dr. Reddy's. The full competitive landscape is in the AskCyborg report.
How can I get the full Biocon Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Biocon Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Biocon Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals & Generic Drugs Manufacturing research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Lupin Limited7Cipla Limited